Oaktree Acquisition Corp. II and Alvotech Complete Business Combination to List on Nasdaq as ALVO
June 15, 2022
Alvotech completed its business combination with Oaktree Acquisition Corp. II, a SPAC sponsored by an affiliate of Oaktree Capital Management, resulting in a Nasdaq listing under ticker symbols ALVO/ALVOW. The deal included a ~$175 million upsized, fully committed PIPE at $10.00 per share and was designed to create a publicly traded, pure-play global biosimilars platform.
- Buyers
- Oaktree Acquisition Corp. II, Oaktree Capital Management, L.P. (via SPAC sponsor affiliate)
- Targets
- Alvotech Holdings S.A.
- Industry
- Biotechnology
- Location
- Iceland
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Teamshares Business Combination With Live Oak Acquisition Corp. V (LOKV) to List on Nasdaq in 2Q 2026
January 20, 2026
Professional Services
Teamshares entered into definitive agreements for a business combination with Live Oak Acquisition Corp. V (NASDAQ: LOKV), which is expected to take Teamshares public on Nasdaq in the second quarter of 2026. The transaction values the combined company at a pro forma enterprise value of $746 million and is expected to deliver up to $333 million of net proceeds through a $126 million PIPE and Live Oak V’s cash in trust.
-
EQT (via Otello BidCo AB) Acquires OX2 AB
October 8, 2024
Energy
EQT Infrastructure VI, through acquisition vehicle Otello BidCo AB, completed a recommended public offer to acquire 100% of OX2 AB at SEK 60 per share and now controls 98.81% of the company; OX2 has applied for delisting from Nasdaq Stockholm. EQT says it will support OX2's evolution from a pure developer to an integrated renewables developer and asset owner and provide additional investment to grow the company's pipeline across onshore/offshore wind, solar and storage.
-
PureTech Acquires Remaining Interest in Alivio Therapeutics
June 16, 2021
Biotechnology
PureTech Health plc acquired the remaining 22% of shares in its Founded Entity, Alivio Therapeutics, integrating Alivio's anti-inflammatory therapeutic programs — including LYT-500 and LYT-503/IMB-150 — into PureTech's Wholly Owned Pipeline. The transaction consolidates PureTech's ownership of Alivio and is expected to fund and advance the programs through PureTech's immunology and related technology capabilities.
-
Atlantic Coastal Acquisition Corp. II Completes Business Combination with Abpro Corporation
November 13, 2024
Biotechnology
Abpro Corporation and Atlantic Coastal Acquisition Corp. II completed their business combination and the combined company will operate as Abpro Holdings, Inc., with Abpro Corporation as a wholly owned subsidiary. The company is expected to begin trading on Nasdaq under the ticker ABP (and ABPWW for warrants); South Korea's Celltrion participated in a $5.0 million PIPE and appointed Soo Young Lee to Abpro's board.
-
Avant Technologies Proposes Acquisition of Ainnova Tech to Consolidate Vision AI JV
May 13, 2025
Healthcare Services
Avant Technologies has entered formal negotiations to acquire its joint-venture partner Ainnova Tech (operating through Ai-nova Acquisition Corp.), aiming to merge the businesses ahead of an FDA pre-submission meeting. The deal is intended to streamline regulatory coordination, speed clinical development and support U.S. market entry for the Vision AI clinical screening platform currently piloted across Latin America.
-
Virgin Group Acquisition Corp. II and Grove Collaborative Complete Business Combination
June 14, 2022
Consumer Products
Virgin Group Acquisition Corp. II (VGII) and Grove Collaborative announced the completion of their previously announced business combination, with the combined company expected to trade as Grove Collaborative Holdings, Inc. on the NYSE under the ticker “GROV.” The transaction included an $86 million PIPE investment from affiliates of the VGII sponsor and new/existing Grove investors, including Lone Pine Capital, Sculptor Capital Management, General Atlantic, and Paul Polman.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.